Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ)
CNY44.49
+2.52 (+6.00%)
CN SHZ Healthcare Biotechnology
Address
Caesar Center 100027
Beijing, CN
Beijing, CN
CEO
Guanyi Wang
Website
fu-rui.com
IPO
2010-01-20
ISIN CNE100000KG1
Description
Inner Mongolia Furui Medical Science Co., Ltd. functions as a dedicated platform offering specialized healthcare services. The company's primary focus lies in the liver disease sector, where it delivers a full spectrum of solutions encompassing accurate disease diagnosis, pharmaceutical treatments, and ongoing chronic condition management. Beyond this, it also provides comprehensive health management facilities and general medical care services. Established in 1998, with its headquarters situated in Beijing, China, the entity was previously known as Inner Mongolia FuRui Pharmaceutical Limited Liability Company.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY44.49
+2.52 (+6.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
-0.43
Float Shares
215.14M
Free Float %
81.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.25% | -18.35% | -11.32% | -31.89% | -34.00% | -36.57% | +26.41% | +56.32% | +269.09% | +122.74% | +340.43% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
44.49
DCF (Levered)
92.44
+107.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
9.18
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✓ MOAT relativo
★ Strong MOAT
-
Revenue growth Biotechnology: +1.6%+18.1% ★ Q1'26: +9.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+37.2% ★ Q1'26: +9.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+14.8% ★ Q1'26: +12.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+25.1% ★ Q1'26: +20.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+15.7% ★ Q1'26: +11.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.27× ★ Q1'26: 0.27× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
604.19M
est: 672.00M (-10.1%)
|
826.99M
est: 672.00M (+23.1%)
|
823.33M
est: 752.00M (+9.5%)
|
867.03M
est: 1.08B (-19.3%)
|
831.74M
est: 988.20M (-15.8%)
|
807.53M
est: 1.13B (-28.2%)
|
898.48M
est: 1.25B (-28.4%)
|
1.15B
est: 1.18B (-2.3%)
|
1.35B
est: 1.48B (-8.7%)
|
1.59B
est: 1.58B (+1.1%)
|
2.03B
1.96B – 2.10B
+28.7% YoY
|
2.49B
2.33B – 2.65B
+22.7% YoY
|
3.03B
2.93B – 3.14B
+21.9% YoY
|
| EBITDA |
138.95M
est: 171.05M (-18.8%)
|
210.77M
est: 171.05M (+23.2%)
|
195.91M
est: 191.42M (+2.3%)
|
164.90M
est: 273.63M (-39.7%)
|
193.45M
est: 251.54M (-23.1%)
|
209.72M
est: 286.39M (-26.8%)
|
221.12M
est: 319.33M (-30.8%)
|
307.52M
est: 300.49M (+2.3%)
|
358.88M
est: 392.81M (-8.6%)
|
504.52M
est: 419.14M (+20.4%)
|
539.35M
520.46M – 558.24M
+28.7% YoY
|
661.95M
619.23M – 704.68M
+22.7% YoY
|
806.76M
778.52M – 835.01M
+21.9% YoY
|
| EBIT |
117.22M
est: 128.73M (-8.9%)
|
175.92M
est: 128.73M (+36.7%)
|
150.33M
est: 144.06M (+4.4%)
|
121.33M
est: 205.94M (-41.1%)
|
142.45M
est: 189.31M (-24.7%)
|
140.38M
est: 215.53M (-34.9%)
|
167.40M
est: 240.32M (-30.3%)
|
240.34M
est: 226.15M (+6.3%)
|
286.69M
est: 305.72M (-6.2%)
|
399.70M
est: 326.21M (+22.5%)
|
419.77M
405.07M – 434.47M
+28.7% YoY
|
515.19M
481.94M – 548.45M
+22.7% YoY
|
627.90M
605.91M – 649.89M
+21.9% YoY
|
| Net Income |
91.69M
est: 97.33M (-5.8%)
|
121.05M
est: 97.33M (+24.4%)
|
61.11M
est: 113.11M (-46.0%)
|
35.42M
est: 155.20M (-77.2%)
|
43.39M
est: 121.00M (-64.1%)
|
61.91M
est: 147.31M (-58.0%)
|
95.47M
est: 170.98M (-44.2%)
|
101.56M
est: 105.22M (-3.5%)
|
113.29M
est: 176.25M (-35.7%)
|
154.09M
est: 168.35M (-8.5%)
|
247.27M
236.01M – 258.53M
+46.9% YoY
|
334.08M
318.87M – 349.28M
+35.1% YoY
|
436.67M
416.79M – 456.54M
+30.7% YoY
|
| SGA |
269.61M
est: 297.49M (-9.4%)
|
389.47M
est: 297.49M (+30.9%)
|
357.90M
est: 332.90M (+7.5%)
|
372.45M
est: 475.89M (-21.7%)
|
376.15M
est: 437.47M (-14.0%)
|
347.54M
est: 498.07M (-30.2%)
|
396.18M
est: 555.35M (-28.7%)
|
527.56M
est: 522.59M (+0.9%)
|
584.24M
est: 638.46M (-8.5%)
|
602.50M
est: 681.25M (-11.6%)
|
876.64M
845.94M – 907.33M
+28.7% YoY
|
1.08B
1.01B – 1.15B
+22.7% YoY
|
1.31B
1.27B – 1.36B
+21.9% YoY
|
| EPS |
0.35
est: 0.37 (-5.4%)
|
0.46
est: 0.37 (+24.3%)
|
0.23
est: 0.43 (-46.5%)
|
0.13
est: 0.59 (-78.0%)
|
0.17
est: 0.46 (-63.0%)
|
0.24
est: 0.56 (-57.1%)
|
0.37
est: 0.65 (-43.1%)
|
0.39
est: 0.40 (-2.5%)
|
0.43
est: 0.67 (-35.8%)
|
0.59
est: 0.64 (-7.8%)
|
0.94
0.90 – 0.98
+46.9% YoY
|
1.27
1.21 – 1.33
+35.1% YoY
|
1.66
1.58 – 1.74
+30.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 4/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
290.68M
OE per share TTM
1.10
Owner's Yield
2.46%
Maintenance CapEx ratio
114.81%
Maint CapEx / Avg PPE
38.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 19 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 108.6K | 0.65% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 428.0K | 0.06% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 156.3K | 0.39% |
| 4 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 9.9K | 0.44% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 117.1K | 0.29% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 31.9K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 14.1K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.57M | 0.06% |
| 9 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 109.4K | 0.28% |
| 10 | Vanguard ESG International Stock ETF VSGX | 0.00% | 21.4K | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
568.6K
Shares Outstanding
264.98M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guanyi Wang | GM & Chairman | — | male |
| Lijuan Deng | Deputy GM & Director | — | female |
| Yong Yang | Deputy GM & Director | — | male |
| Zhi Guo Shen | Deputy GM & Financial Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300049.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
